PTC Therapeutics, Inc.
- PTCT
- NASDAQ
- Biotechnology
- Rare Genetic Disease Therapies
- Biopharmaceutical R&D
$63.00
Today +2.39%Quote Oct 20, 2026, 02:55 PM UTC
−5.87%over the last month
Max drawdown −10.2%From 1-month high −6.7%3 months −21.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About PTC Therapeutics
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders.
Where the money comes from
Q2 2026 revenue $360.5M
- Product$238.8M66.2%
- Royalty$71.1M19.7%
- Collaboration and License Revenue$50.6M14.0%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
991
Market value
$5.26B
Quote Oct 20
Floor
$61.02
3.1% below price
Resistance
$63.25
0.4% above price
Price vs analyst targets
26 analysts
Lowest target
$75.00Highest target
$137.00
$75.00Highest target
$137.00
- Price $63.00
- Average target $102.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 63% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PTCTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free